PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong 510440, China.\', \'Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong 511430, China.\', \'Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, China.\', \'National Institutes for Food and Drug Control, Beijing 100050, China.\', \'Gaozhou Center for Disease Control and Prevention, Maoming, Guangdong 525000, China.\', \'Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.\', \'Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People\'s Hospital, Shenzhen, Guangdong 518112, China.\', \'Livzon Bio Inc., Zhuhai, Guangdong 519045, China.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1097/CM9.0000000000001702
?:hasPublicationType
?:journal
  • Chinese medical journal
is ?:pmid of
?:pmid
?:pmid
  • 34310400
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.52
?:rankingScore_hIndex
  • 52
is ?:relation_isRelatedTo_publication of
?:title
  • Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34310400>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34310400>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all